BRAF and melanoma: To meet these challenges, in a previous study we have designed, developed, and validated, for both tissue samples and liquid biopsy specimens, a narrow NGS gene panel (SiRe®) that covers 568 clinically relevant mutations in six genes (EGFR, KRAS, NRAS, BRAF, cKIT, and PDGFRα) involved in NSCLC, gastrointestinal stromal tumor, mCRC, and melanoma (19–23).